CAS Number: 841205-47-8
Description
LIQUID OSTARINE (MK-2866) – THE ULTIMATE GUIDE
Ostarine, also known as MK-2866, GTX-024, or Enobosarm, is one of the most well-researched and widely recognized selective androgen receptor modulators (SARMs). Originally developed in the late 1990s, Ostarine was designed as a potential treatment for conditions like osteoporosis, muscle wasting, and insulin resistance. Today, it remains a focal point of clinical research due to its unique ability to selectively target androgen receptors without the harsh side effects commonly associated with anabolic steroids, testosterone, or human growth hormone.
WHY OSTARINE STANDS OUT IN CLINICAL RESEARCH
Ostarine’s selective action makes it a promising candidate for research, particularly in female and elderly populations where traditional anabolic treatments may not be suitable. Studies have shown that Ostarine is generally well-tolerated, with doses of up to 18mg per day administered safely over 12 months in female cancer patients. Unlike many anabolic agents, Ostarine is orally bioavailable, eliminating the need for injections.
While Ostarine shows significant potential, it’s important to note that research is ongoing. Potential side effects, such as testosterone suppression in males and menstrual irregularities in females, are still being studied. Long-term effects and interactions with other substances remain under investigation.
POTENTIAL BENEFITS OF OSTARINE IN RESEARCH STUDIES
Research on Ostarine has highlighted several potential benefits, including:
- Enhanced muscle growth and strength
- Increased protein synthesis
- Improved bone density and health
- Accelerated recovery of connective tissues
- Reduction in body fat and support for weight loss
- Boosted energy levels
- Positive effects on heart health
It’s crucial to emphasize that Ostarine is not approved by the FDA for human consumption and is strictly intended for laboratory research purposes. It should not be confused with dietary supplements or sports performance enhancers.
KEY RESEARCH FINDINGS ON OSTARINE (MK-2866)
- Muscle and Strength Benefits: A 2011 study demonstrated that Ostarine significantly increased lean body mass, muscle strength, and physical function in elderly men and postmenopausal women.
- Bone Health: A 2019 study on ovariectomized rats found that Ostarine improved bone healing and stimulated muscle growth.
- Fat Metabolism: Research on Wistar rats revealed that Ostarine reduced fat-mediating hormones like leptin, suggesting potential benefits for fat loss.
- Osteoporosis Support: Another 2019 study showed that Ostarine increased bone mineral density and reduced osteoporosis symptoms in postmenopausal rat models.
POTENTIAL SIDE EFFECTS AND SAFETY CONSIDERATIONS
As one of the oldest and most studied SARMs, Ostarine has a well-documented profile. However, research is still uncovering its full range of effects. Potential side effects may include:
- Testosterone suppression in males
- Menstrual irregularities in females
- Possible liver strain or increased hematocrit levels
- Insomnia or lethargy in some cases
The FDA has issued warnings about the misuse of Ostarine, emphasizing that it is not approved for human use and may pose serious health risks if abused.
LIQUID OSTARINE (MK-2866) PRODUCT DETAILS
- CAS Number: 841205-47-8
- Molecular Formula: C19H14F3N3O3
- Molar Mass: 389.330 g/mol
- Half-Life: 24 hours
- Classification: Selective Androgen Receptor Modulator (SARM)
Product Specifications:
- 30ml liquid Ostarine per bottle
- Concentration: 25mg per milliliter
- Includes a graduated 1mL glass pipette for precise measurement
- UV-resistant glass bottle to minimize degradation
- Tamper-proof seal for safety during transit
- Less than 5% variance in concentration for consistent results
- Formulated to prevent evaporation during storage
Storage Instructions: Store in a cool, dry place away from direct sunlight to maintain optimal shelf life.
Disclaimer: This product is intended for laboratory research purposes only. It is not approved for human consumption, nor is it a dietary or sports supplement.
REFERENCES
- Dalton JT, et al. (2011). The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women. PubMed.
- Hoffmann DB, et al. (2019). Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis. PubMed.
- Smith MR, et al. (2019). A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. PubMed.
- Effect of ostarine (enobosarm/GTX024) on adipocyte metabolism in Wistar rats. PubMed.
Disclaimer: This product is intended for research purposes only. It is not intended for human consumption, medical treatment, or therapeutic use without professional oversight.
There are no reviews yet.